The Sechenov First Moscow State Medical University and the Association of Pharmaceutical Manufacturers of the EAEU (APMEAEU) have signed a cooperation agreement at the 32nd Russian Pharmaceutical Forum named after N.A. Semashko. It is aimed at creating innovative pharmaceuticals, developing methods for long-term forecasting of drug needs, and providing conditions for the development of exports of Russian pharmaceutical products.
“Our common goal is to develop the production of innovative drugs to achieve technological leadership in the industry. We and our partner APMEAEU are facing an ambitious task – to achieve an increase in Russian production of new original medicines with an expected volume of 150-200 billion rubles by 2030 and over 300 billion rubles by 2036,” said Vadim Tarasov, vice-rector for Scientific and Technological Development at Sechenov University.
The cooperation includes the development of methods for long-term forecasting of drug needs, the formation of a list of innovative drugs in demand by the healthcare system, as well as support for the domestic production of pharmaceutical substances. Other areas include the development of export accessibility of Russian medicines in the EAEU, CIS and other friendly countries. The parties also plan to hold joint research-to-practice events.
The 32nd Russian Pharmaceutical Forum named after N. A. Semashko in St. Petersburg outlined the key vectors of the industry’s development. The focus was on updating the Pharma 2030 strategy, controlling drug prices and supporting the localization of pharmaceutical production. Read about the changes that await the industry in the GxP News article.
